Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Joe who wrote (1160)	6/23/1998 11:23:00 AM
From: Sylvester	Read Replies (1) \| Respond to of 4140

From the clinical side. Most patients treated for hyperopia will not be covered by health insurance. Low price plus non-invasive would seem to give SNRS a huge advantage, tempered somewhat by what opthamologists need to purchase for the upgrade to the VISX procedure. don't expect to see a lot of offices having both lasers so if the VISX hyperopic treatment does not require a new laser, doctors will not have to buy Sunrise equipment. That's bad although it has nothing to do with today's stock price. We may not be looking at a $50 stock here folks but $25 aint bad. It's just how and when. Regards, Slyvester